Synthesizing microorganisms beyond tradition: Bactolife unveils American debut with an interesting novel method for intestinal health management

Bactolife, a Danish startup, is set to launch a novel category of gut health ingredients next year, targeting specific consumer groups such as travelers, those experiencing periods of heightened stress, and individuals with metabolites associated with common types of E. coli. The company's binding proteins, inspired by immunoglobulin fragments found in camelid milk, are set to provide a targeted defense against harmful microbial toxins, complementing existing gut health strategies like probiotics and prebiotics without disrupting the microbiome [1][2].

These binding proteins work by selectively binding to harmful metabolites produced by unhealthy gut bacteria, effectively neutralizing these toxins without disrupting the beneficial microbiome. Unlike probiotics, which add beneficial bacteria, and antibiotics, which kill bacteria broadly, Bactolife’s approach is a precision tool: the engineered binding proteins target and lock onto specific bacterial toxins, maintaining microbiome balance while neutralizing harmful effects [1].

The binding proteins are vegan-friendly, allergen-free, and lactose-free, making them suitable for a wide range of food and supplement applications. They are also heat and pH stable, ensuring their effectiveness across various conditions. In addition, the proteins are highly effective in very small doses, typically between 100-200 milligrams [1][2].

Bactolife engineers microbes to express binding proteins at scale via precision fermentation, rather than extracting them from camel milk. The company is currently in discussions with potential partners, including supplement brands and healthcare practitioner brands, and has partnership agreements in place for next year's launch. Bactolife has raised $50 million to date, with backing from Novo Holdings, ATHOS, and the Gates Foundation [1][2].

The awareness and interest in the microbiome have increased exponentially, according to Liz Spence, a food and ag industry veteran who has been hired to spearhead Bactolife's operations in the US. The fact that prebiotics are now in the mass market is a huge indicator of growing consumer and industry interest in the microbiome. Bactolife plans to launch a whole portfolio of binding proteins over the next three to five years [1][2].

The company is preparing submissions in Asian countries and as a novel food in Europe. Bactolife's first two binding proteins are expected to receive self-GRAS status in the middle of next year [1][2]. As consumers become more aware and interested in the power of their microbiome, Bactolife's binding proteins are poised to become a game-changer in the gut health market.

References: [1] Bactolife Press Release, [Date], [Link] [2] Bactolife Website, [Date], [Link]

Synthesizing microorganisms beyond tradition: Bactolife unveils American debut with an interesting novel method for intestinal health management